Cubist Systematic Strategies LLC Takes Position in LifeStance Health Group, Inc. $LFST

Key Points

• Cubist Systematic Strategies LLC acquired 308,333 shares of LifeStance Health Group, Inc. for approximately $2,053,000, representing a 0.08% stake in the company.
• Major shareholders Silversmith Partners and Summit Partners sold a combined total of over 12 million shares at an average price of $5.07, significantly reducing their ownership.
• LifeStance Health Group's stock recently received multiple upgrades, with UBS raising its price target from $8.50 to $9.00 and the consensus rating shifting to "Moderate Buy."

Cubist Systematic Strategies LLC bought a new position in shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 308,333 shares of the company's stock, valued at approximately $2,053,000. Cubist Systematic Strategies LLC owned about 0.08% of LifeStance Health Group as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in LFST. Vanguard Group Inc. grew its stake in LifeStance Health Group by 5.0% in the 1st quarter. Vanguard Group Inc. now owns 11,221,237 shares of the company's stock worth $74,733,000 after buying an additional 531,841 shares in the last quarter. Jennison Associates LLC boosted its stake in LifeStance Health Group by 2.1% during the first quarter. Jennison Associates LLC now owns 8,255,236 shares of the company's stock worth $54,980,000 after buying an additional 168,856 shares during the period. Wellington Management Group LLP raised its holdings in shares of LifeStance Health Group by 2.3% in the first quarter. Wellington Management Group LLP now owns 5,399,293 shares of the company's stock valued at $35,959,000 after acquiring an additional 123,056 shares in the last quarter. Parcion Private Wealth LLC purchased a new stake in shares of LifeStance Health Group during the first quarter worth about $15,670,000. Finally, Northern Trust Corp boosted its position in LifeStance Health Group by 11.7% in the 4th quarter. Northern Trust Corp now owns 1,591,776 shares of the company's stock worth $11,731,000 after purchasing an additional 166,731 shares in the last quarter. 85.50% of the stock is currently owned by institutional investors and hedge funds.

LifeStance Health Group Trading Down 2.1%

Shares of NASDAQ LFST traded down $0.12 during trading hours on Tuesday, reaching $5.49. The stock had a trading volume of 2,510,332 shares, compared to its average volume of 2,584,221. The business's fifty day moving average price is $4.78 and its two-hundred day moving average price is $5.79. The firm has a market cap of $2.14 billion, a price-to-earnings ratio of -109.80 and a beta of 1.17. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.19. LifeStance Health Group, Inc. has a 52-week low of $3.74 and a 52-week high of $8.61.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. The business had revenue of $345.31 million for the quarter, compared to analyst estimates of $345.05 million. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The company's revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.06) EPS. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts expect that LifeStance Health Group, Inc. will post -0.18 EPS for the current fiscal year.

Analyst Ratings Changes

LFST has been the subject of several recent research reports. BTIG Research assumed coverage on LifeStance Health Group in a research note on Friday, July 25th. They issued a "buy" rating and a $8.00 price objective for the company. UBS Group raised their target price on LifeStance Health Group from $8.50 to $9.00 and gave the company a "buy" rating in a report on Friday, August 8th. Finally, Wall Street Zen upgraded LifeStance Health Group from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.50.

Insiders Place Their Bets

In related news, major shareholder Summit Partners L. P sold 8,407,643 shares of the company's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the completion of the transaction, the insider directly owned 33,524,715 shares in the company, valued at $169,970,305.05. This represents a 20.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Darren M. Black sold 8,407,643 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the sale, the director directly owned 33,524,715 shares in the company, valued at approximately $169,970,305.05. This represents a 20.05% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,407,643 shares of company stock valued at $103,466,750 over the last quarter. Company insiders own 6.60% of the company's stock.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.